Printer Friendly

ABBOTT LABORATORIES INTRODUCES NEW QUINOLONE ANTIBIOTIC

 ABBOTT LABORATORIES INTRODUCES NEW QUINOLONE ANTIBIOTIC
 ABBOTT PARK, Ill., Jan. 31 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) announced today that Omniflox (temafloxacin), a new quinolone antibiotic to treat certain lower respiratory tract infections, genitourinary infections and skin infections, has cleared FDA review.
 Omniflox is indicated for the treatment of lower respiratory tract infections (pneumonia, bronchitis), genitourinary infections (prostatitis, urinary tract infection) and skin infections.
 Omniflox, discovered and developed by Abbott scientists, is the second new antibiotic introduced in the U.S. by the company in recent months. Biaxin (clarithromycin), a macrolide antibiotic, cleared FDA review on Oct. 31, 1991.
 "The market for antibiotics is one of the largest and most attractive in medicine," said Paul Clark, senior vice president, pharmaceutical operations. "With Biaxin and Omniflox, we are well- positioned to compete successfully in this marketplace during the 1990s."
 Abbott Laboratories and ICI Pharmaceuticals Group will co-promote Omniflox in the United States. "We are very enthusiastic about the Abbott/ICI partnership on this exciting product, and confident that our combined efforts will lead to a very successful Omniflox introduction into a challenging marketplace," commented Robert C. Black, president of ICI Pharmaceuticals Group. Additionally, co-promotion or co-marketing agreements have been reached between Abbott and ICI in the United Kingdom, Sweden, Germany, Spain and Italy.
 TAP Pharmaceuticals, a joint venture of Abbott and Takeda Chemical Industries of Japan, will also co-promote Omniflox in the United States with Abbott to urologists and obstetricians/gynecologists.
 Temafloxacin has been approved in eight other countries, including the United Kingdom and Italy, and is awaiting approval in over 30 other countries.
 Adult oral antibiotics achieved U.S. sales of $2.2 billion in 1990, a 15 percent increase over 1989.
 Respiratory infections are the largest category for which oral anti- infective products are used. In 1990, more than 50 percent of all prescriptions in the adult oral antibiotic market were written for respiratory infections.
 Genitourinary infections represented the next largest group of infections treated, accounting for 20 percent of all drug uses. Urinary tract infections accounted for nearly one-third of all quinolone prescriptions, making them the most frequently treated infections for this class.
 Abbott Laboratories is a worldwide manufacturer of health care products employing nearly 46,000 people. In 1991, the company's sales and net earnings were $6.9 billion and $1.1 billion respectively, with earnings per share of $2.55.
 ICI Pharmaceuticals, a business unit of ICI PLC, is a major research-based developer and manufacturer of prescription products, and employs nearly 13,000 people. In 1991, ICI Pharmaceuticals worldwide sales through September were nearly $2 billion. The U.S. organization, ICI Pharmaceuticals Group, is based in Wilmington, Delaware and includes two sales units, ICI Pharma and Stuart Pharmaceuticals.
 -0- 1/31/92
 /CONTACT: Jeff Newton, 708-937-5968, or Matt Kuhn, 708-937-2993, both of Abbott Laboratories, or Eileen Cunniffe of ICI Pharmaceuticals Group, 302-886-7860/
 (ABT) CO: Abbott Laboratories; ICI Pharmaceuticals Group ST: Illinois IN: MTC SU: PDT


PS -- NY056 -- 5728 01/31/92 15:32 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 31, 1992
Words:497
Previous Article:JEFFERSON BANCORP REPORTS FINANCIAL RESULTS FOR YEAR ENDED DEC. 31, 1991
Next Article:NIH AWARDS GEORGETOWN UNIVERSITY GRANT TO EVALUATE AIDS THERAPIES
Topics:


Related Articles
ABBOTT INTRODUCES NEW MACROLIDE ANTIBIOTIC IN U.S.
ABBOTT FILES NEW DRUG APPLICATION FOR PEDIATRIC ANTIBIOTIC
ABBOTT AND SMITHKLINE BEECHAM SIGN MARKETING AND DISTRIBUTION AGREEMENT
SECOND MICHIGAN OMNIFLOX CASE FILED AGAINST ABBOTT LABORATORIES
Abbott Laboratories Announces Agreement with Wakunaga to Develop and Market Two Anti-Infective Compounds.
American Chemical Society and Royal Society of Chemistry Honor Abbott for Important Medical Contribution.
Abbott Laboratories Announces Availability of New, Once-Daily Biaxin(R) XL (clarithromycin extended-release tablets).
Abbott Laboratories Submits Supplemental NDA For Biaxin XL(R) (Clarithromycin Extended-Release Tablets) for Community-Acquired Pneumonia (CAP)...
Abbott Laboratories Receives FDA Approval For Community-Acquired Pneumonia (CAP) Indication For Biaxin(R) XL (Clarithromycin Extended-Release...
Clarithromycin (Biaxin(R)) Active Against Anthrax in Vitro; - Data Suggest Low Emergence of Biaxin Resistance In Vitro -.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters